Medpace's Q1 2025 Earnings Call: Navigating Contradictions in Business Environment, Cancellation Rates, and Book-to-Bill Expectations
Earnings DecryptWednesday, Apr 23, 2025 9:44 pm ET

Business environment and cancellation rates, book-to-bill ratio expectations, competitive environment and pricing, issues with funding uncertainties are the key contradictions discussed in Medpace's latest 2025Q1 earnings call.
Revenue and Backlog Trends:
- reported revenue of $558.6 million for Q1 2025, representing a 9.3% year-over-year increase.
- The ending backlog as of March 31, 2025, was approximately $2.8 billion, a 2.1% decrease from the prior year.
- The decrease in backlog was due to high pipeline cancellations in prior quarters, impacting Q1 and future projected backlog net awards.
Book-to-Bill Ratio and Cancellations:
- The company's net book-to-bill ratio was 0.90 in Q1 2025, indicating a decrease in net new business awards entering backlog.
- Cancellations were modestly elevated in Q1, with pre-backlog cancellations being significantly worse, affecting the book-to-bill ratio and backlog growth.
Financial Performance and Margin Trends:
- EBITDA for Q1 2025 increased by 2.6% year-over-year to $118.6 million, but the EBITDA margin decreased to 21.2%, down from 22.6% in the prior year period.
- The margin decrease was attributed to employee-related costs and foreign exchange impacts due to a weakening U.S. dollar.
Share Repurchase and Capital Allocation:
- Medpace repurchased approximately 1.19 million shares or $389.8 million during the first quarter, with $344.8 million remaining under the share repurchase authorization program.
- The company continues to take an opportunistic approach to share repurchases, leveraging share price volatility for strategic capital allocation.
Revenue and Backlog Trends:
- reported revenue of $558.6 million for Q1 2025, representing a 9.3% year-over-year increase.
- The ending backlog as of March 31, 2025, was approximately $2.8 billion, a 2.1% decrease from the prior year.
- The decrease in backlog was due to high pipeline cancellations in prior quarters, impacting Q1 and future projected backlog net awards.
Book-to-Bill Ratio and Cancellations:
- The company's net book-to-bill ratio was 0.90 in Q1 2025, indicating a decrease in net new business awards entering backlog.
- Cancellations were modestly elevated in Q1, with pre-backlog cancellations being significantly worse, affecting the book-to-bill ratio and backlog growth.
Financial Performance and Margin Trends:
- EBITDA for Q1 2025 increased by 2.6% year-over-year to $118.6 million, but the EBITDA margin decreased to 21.2%, down from 22.6% in the prior year period.
- The margin decrease was attributed to employee-related costs and foreign exchange impacts due to a weakening U.S. dollar.
Share Repurchase and Capital Allocation:
- Medpace repurchased approximately 1.19 million shares or $389.8 million during the first quarter, with $344.8 million remaining under the share repurchase authorization program.
- The company continues to take an opportunistic approach to share repurchases, leveraging share price volatility for strategic capital allocation.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet